OKYO Pharma Limited (AIM:OKYO) Appointment to Scientific Advisory Board

OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board

World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma

London and New York, NY, February 23, 2023 OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces the appointment of Jay S. Pepose, M.D., Ph.D., Founder and Medical Director of the Pepose Vision Institute and Professor of Clinical Ophthalmology at Washington University School of Medicine, to OKYO’s Scientific Advisory Board (SAB). In this role Dr. Pepose will help guide OKYO’s clinical programs for OK-101 for the treatment of DED. The Company anticipates opening its Phase 2 clinical trial of OK-101 to enrollment in the first quarter of 2023.

“As a well-established thought leader in eye disease, Dr. Pepose is an ideal choice to help us raise the profile of OK-101 and educate the clinical community about its potential to treat DED,” said Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma. “As a distinguished ophthalmologic surgeon, researcher and entrepreneur, we look forward to his guidance as we advance OK-101 toward the clinic in the coming weeks.”

“Dry eye is a prevalent, multifactorial disease of the ocular surface, in which ocular surface inflammation and neurosensory abnormalities play etiological roles,” said Dr. Pepose, M.D. Ph.D. “In animal models, OK-101’s ability to reduce ocular pain, suppress ocular inflammation, and normalize goblet cell density make it an attractive candidate to further evaluate in clinical trials of dry eye disease.”

Dr. Pepose has nearly 40 years of experience as both a treating physician and a widely published researcher. He is the founder and Medical Director of the Pepose Vision Institute and a professor of Clinical Ophthalmology & Visual Sciences at Washington University School of Medicine in St. Louis. Dr. Pepose is actively involved in clinical trials and has served as an investigator on over 30 studies evaluating new therapeutics and technology in a broad range of ophthalmic indications, including dry eye. He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.

Dr. Pepose received an A.B. and M.A. in neurophysiology from Brandeis University and completed the M.D. Ph.D. program at the UCLA School of Medicine. Dr. Pepose completed his ophthalmology residency at the Wilmer Institute at the Johns Hopkins Medical Center and his fellowship training at Georgetown University Medical Center.

About OKYO

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com.


OKYO Pharma Limited

Gary S. Jacob, Chief Executive Officer

+44 (0)20 7495 2379

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.